Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for biib
237.87
+9.35 (4.09%)
Real-time:   1:07PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 232.00 - 239.16
52 week 232.00 - 420.99
Open 232.87
Vol / Avg. 1.59M/2.08M
Mkt cap 53.01B
P/E 14.61
Div/yield     -
EPS 16.28
Shares 219.05M
Beta 0.83
Inst. own 88%
Jul 21, 2016
Q2 2016 Biogen Inc Earnings Release - 9:30AM EDT - Add to calendar
Jul 21, 2016
Q2 2016 Biogen Inc Earnings Call - 8:30AM EDT - Add to calendar
Jun 9, 2016
Biogen Inc Annual Shareholders Meeting (Estimated)
Jun 8, 2016
Biogen Inc Annual Shareholders Meeting
May 3, 2016
Biogen Inc Conference Call on Hemophilia Spin off
Apr 21, 2016
Q1 2016 Biogen Inc Earnings Release
Apr 21, 2016
Q1 2016 Biogen Inc Earnings Call
Apr 11, 2016
Biogen Inc at Goldman Sachs Alzheimer's Symposium - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 35.54% 33.50%
Operating margin 50.55% 45.44%
EBITD margin - 52.17%
Return on average assets 19.35% 21.32%
Return on average equity 39.54% 35.15%
Employees 7,350 -
CDP Score - 96 C

Address

225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 68
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 59
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Global Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Michael D Ehlers M.D., Ph.D. Executive Vice President of Research and Development
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 62
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 53
Bio & Compensation  - Reuters
Adam M. Koppel M.D. Ph.D. Executive Vice President - Strategy and Business Development
Age: 46
Bio & Compensation  - Reuters